Categories: HealthcareNews

Koya Medical to Present at the J.P. Morgan 2026 Healthcare Conference

DALLAS and SAN FRANCISCO, Jan. 5, 2026 /PRNewswire/ — Koya Medical (“Koya”), an emerging medtech innovator advancing patient-centered solutions in peripheral vascular health, has announced its participation in the J.P. Morgan Healthcare Conference on Wednesday January 14th at 9:00am PST at the Westin St. Francis Hotel in San Francisco.

CEO Andy Doraiswamy will highlight the company’s growth and commercial momentum for its portfolio—including Dayspring® non-pneumatic compression treatment for chronic edema—and share progress on the clinical research for its pipeline.

About Koya Medical

Founded in 2018 and headquartered in Dallas, Koya Medical is redefining vascular health with solutions designed to support the continuum of care from clinic to home. Inspired by a personal journey, Koya’s mission is to close treatment gaps and raise treatment expectations for vascular health.

Why Vascular Health Matters

More than 35 million Americans live with venous and lymphatic diseases—serious yet often overlooked conditions that can severely impact mobility, quality of life, and long-term health—highlighting the urgent need for modern, evidence-based, and scalable solutions.

Learn more at www.koyamedical.com and follow Koya on LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/koya-medical-to-present-at-the-jp-morgan-2026-healthcare-conference-302650888.html

SOURCE Koya Medical

Staff

Recent Posts

MEDITECH Announces the Passing of Founder and Chairman A. Neil Pappalardo

Reflections on his 56-year legacy as a tech pioneer and founder of the EHR industryCANTON,…

1 hour ago

eClinicalWorks and Sunoh.ai Assist Healthy Horizons Clinic Save Over Two Hours Daily on Clinical Documentation

Multispecialty practice transforms patient care, improves operational efficiency, and increases patient engagement with AI medical…

1 hour ago

TRNR Publishes Comprehensive Sportstech Documentation for Shareholders

Timeline and Source Materials Now Available at interactivestrength.com/sportstech AUSTIN, TEXAS / ACCESS Newswire / January…

1 hour ago

KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of RYSTIGGO® (rozanolixizumab-noli), Expanding Label for FreedomEDGE® Infusion System

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading…

4 hours ago

Hologic Announces Financial Results for First Quarter of Fiscal 2026

– Revenue of $1,047.8 Million Grows 2.5% – – GAAP Diluted EPS of $0.79 Decreases…

4 hours ago

Illumina completes acquisition of SomaLogic

Deeply expands leadership in proteomics and multiomicsCombined capabilities bring high scalability, flexibility, and affordability into protein…

4 hours ago